Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period

Conference contribution


Publication Details

Author(s): Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Oberg K, Warner RRP, Kunz PL, Kunz PL, Grande E, Valle JW, Dillon JS, Lapuerta P, Banks P, Jackson S, Pavel ME
Publication year: 2018
Volume: 47
Journal issue: 3
Pages range: 341-342
ISSN: 0885-3177


FAU Authors / FAU Editors

Pavel, Marianne Ellen
Medizinische Klinik 1 - Gastroenterologie, Pneumologie und Endokrinologie


External institutions with authors

Dana–Farber Cancer Institute
Hospital Universitario Ramón y Cajal
Icahn School of Medicine at Mount Sinai
Lexicon Pharmaceuticals, Inc.
Royal Free Hospital
Stanford University
UCSF Helen Diller Family Comprehensive Cancer Center
University of Iowa
University of Kentucky
University of Manchester
Uppsala University
Zentralklinikum Bad Berka


How to cite

APA:
Hoersch, D., Kulke, M.H., Caplin, M.E., Anthony, L.B., Bergsland, E., Oberg, K.,... Pavel, M.E. (2018). Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period. (pp. 341-342).

MLA:
Hoersch, Dieter, et al. "Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period." 2018. 341-342.

BibTeX: 

Last updated on 2019-25-01 at 07:38